Exhonit repurchased InGen BioSciences, a company specialized in the development and commercialization of innovative medical devices in vitro diagnostics for € 18 million. The founding managers and VCs Target (Amundi and Innoven Partners) were paid in part (€ 10 million) in Exonhit titles. The company’s name has been changed to Diaxonhit following the transaction.

Seller’s Attorneys: Pinot de Villechenon & Associés (Gilles Roux)
Purchaser’s Attorneys: Jones Day (Renaud Bonnet, Jean-Gabriel Griboul) – Brandi Partners (Laurent Beauvois)

La Lettre Capital Finance, No. 1083 of November 12, 2012, p.2